Prognosis For Patients Diagnosed With Bronchiectasis

EP: 1.Overview of Bronchiectasis

Now Viewing

EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis

EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis

EP: 4.Complications Associated With Bronchiectasis

EP: 5.Current Treatment Options For Bronchiectasis

EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care

EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment

EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis

EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis

EP: 10.Bronchiectasis Exacerbation Management

EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis

EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis

EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis

EP: 14.Other Challenges With Bronchiectasis and Key Takeaways

This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the prognosis of bronchiectasis.

The prognosis varies based on severity, especially if treated aggressively early on. With treatment, most patients can have a normal life expectancy, though slow symptom progression often occurs. At initial evaluation, patients are counseled that bronchiectasis will likely persist lifelong as an annoyance rather than severely limiting. Evidence supports improved quality of life with specialty center care, though high-quality generalist care can replicate good outcomes.

The bronchiectasis severity index stratifies prognosis based on multiple factors like age, comorbidities, lung function, and chronic bacterial airway infection. Most patients have nonsevere disease without dramatically shortened survival. Death directly related to bronchiectasis is unusual.

Worse outcomes are predicted by chronic Pseudomonas airway infection and frequent exacerbations of 3 or more per year despite aggressive therapy. These patients tend to remain frequent exacerbators.

There are no FDA-approved bronchiectasis treatments. One nonapproved therapy, chronic low-dose macrolide antibiotics, can reduce exacerbation frequency, but most frequent exacerbators stay that way.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.